96 related articles for article (PubMed ID: 21309408)
1. Serum p53 antibody is a useful tumor marker of early colorectal cancer.
Noaki R; Kawahara H; Watanabe K; Ushigome T; Kobayashi S; Yanaga K
Int Surg; 2010; 95(4):287-92. PubMed ID: 21309408
[TBL] [Abstract][Full Text] [Related]
2. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma.
Shimada H; Takeda A; Arima M; Okazumi S; Matsubara H; Nabeya Y; Funami Y; Hayashi H; Gunji Y; Suzuki T; Kobayashi S; Ochiai T
Cancer; 2000 Oct; 89(8):1677-83. PubMed ID: 11042560
[TBL] [Abstract][Full Text] [Related]
3. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
[TBL] [Abstract][Full Text] [Related]
4. Metastatic potential in T1 and T2 colorectal cancer.
Fang WL; Chang SC; Lin JK; Wang HS; Yang SH; Jiang JK; Chen WC; Lin TC
Hepatogastroenterology; 2005; 52(66):1688-91. PubMed ID: 16334758
[TBL] [Abstract][Full Text] [Related]
5. P53 correlates positively with VEGF in preoperative sera of colorectal cancer patients.
Famulski W; Sulkowska M; Wincewicz A; Kedra B; Pawlak K; Zalewski B; Sulkowski S; Koda M; Baltaziak M
Neoplasma; 2006; 53(1):43-8. PubMed ID: 16416012
[TBL] [Abstract][Full Text] [Related]
6. p53 as an indicator of lymph node metastases in invasive early colorectal cancer.
Makino M; Yamane N; Taniguchi T; Honboh T; Kurayoshi K; Kaibara N
Anticancer Res; 2000; 20(3B):2055-9. PubMed ID: 10928151
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic significance in serum presence of anti-p53 antibody in patients with colorectal carcinoma.
Nozoe T; Yasuda M; Honda M; Inutsuka S; Korenaga D
Hepatogastroenterology; 2007; 54(77):1422-5. PubMed ID: 17708268
[TBL] [Abstract][Full Text] [Related]
8. Normalization of serum p53 antibody levels in patients after curative resection for colorectal cancer.
Kawahara H; Watanabe K; Enomoto H; Toyama Y; Akiba T; Yanaga K
Anticancer Res; 2013 May; 33(5):2221-5. PubMed ID: 23645779
[TBL] [Abstract][Full Text] [Related]
9. Serum p53 antibody as tumor marker for follow-up of colorectal cancer after curative resection.
Tang R; Yeh CY; Wang JY; Changchien CR; Chen JS; Hsieh LL
Ann Surg Oncol; 2009 Sep; 16(9):2516-23. PubMed ID: 19565285
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
[TBL] [Abstract][Full Text] [Related]
11. Preoperative serum vascular endothelial growth factor-a is a marker for subsequent recurrence in colorectal cancer patients.
Alabi AA; Suppiah A; Madden LA; Monson JR; Greenman J
Dis Colon Rectum; 2009 May; 52(5):993-9. PubMed ID: 19502868
[TBL] [Abstract][Full Text] [Related]
12. CXCL5, a promoter of cell proliferation, migration and invasion, is a novel serum prognostic marker in patients with colorectal cancer.
Kawamura M; Toiyama Y; Tanaka K; Saigusa S; Okugawa Y; Hiro J; Uchida K; Mohri Y; Inoue Y; Kusunoki M
Eur J Cancer; 2012 Sep; 48(14):2244-51. PubMed ID: 22197219
[TBL] [Abstract][Full Text] [Related]
13. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
Suzuki H; Akakura K; Igarashi T; Ueda T; Ito H; Watanabe M; Nomura F; Ochiai T; Shimada H
J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872
[TBL] [Abstract][Full Text] [Related]
14. Circulating form of human vascular adhesion protein-1 (VAP-1): decreased serum levels in progression of colorectal cancer and predictive marker of lymphatic and hepatic metastasis.
Toiyama Y; Miki C; Inoue Y; Kawamoto A; Kusunoki M
J Surg Oncol; 2009 May; 99(6):368-72. PubMed ID: 19204971
[TBL] [Abstract][Full Text] [Related]
15. [Rule of lymph node metastasis in colorectal cancer and its affecting factors].
Tu SL; Ye ZY; Deng GL; Zhao ZS; Dong QJ; Zheng BA; Ding LP; Cao HF
Zhonghua Wei Chang Wai Ke Za Zhi; 2007 May; 10(3):257-60. PubMed ID: 17520386
[TBL] [Abstract][Full Text] [Related]
16. Serum anti-p53 antibodies as a diagnostic tumor marker: observations in patients with malignant and premalignant oral cavity lesions.
Porrini R; Vercellino V; Rocchetti V; RenĂ² F; Giorda E; Pomato E; Cannas M; Sabbatini M
Minerva Stomatol; 2010 May; 59(5):233-9, 239-43. PubMed ID: 20502428
[TBL] [Abstract][Full Text] [Related]
17. The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters.
Gao RJ; Bao HZ; Yang Q; Cong Q; Song JN; Wang L
Breast Cancer Res Treat; 2005 Sep; 93(2):111-5. PubMed ID: 16187230
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of predictive biomarkers for therapeutical strategies in colorectal cancer.
Gasser M; Gerstlauer C; Grimm M; Bueter M; Lebedeva T; Lutz J; Maeder U; Ribas C; Ribas C; Nichiporuk E; Thalheimer A; Heemann U; Thiede A; Meyer D; Waaga-Gasser AM
Ann Surg Oncol; 2007 Apr; 14(4):1272-84. PubMed ID: 17211733
[TBL] [Abstract][Full Text] [Related]
19. [Detection of serum p53 antibodies in colorectal cancer patients and the clinical significance of postoperative monitoring].
Takeda A; Shimada H; Nakajima K; Imaseki H; Okazumi S; Takayama W; Hayashi H; Iwasaki K; Sasagawa S; Chou A; Natsume T; Kouno T; Kondou S; Maeda T; Hori S; Suzuki T; Ochiai T; Isono K
Gan To Kagaku Ryoho; 1999 Dec; 26(14):2189-94. PubMed ID: 10635303
[TBL] [Abstract][Full Text] [Related]
20. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group.
Shimada H; Ochiai T; Nomura F;
Cancer; 2003 Feb; 97(3):682-9. PubMed ID: 12548611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]